Celltrion reported KRW17.04B in Interest Expense on Debt for its fiscal quarter ending in March of 2025.


Interest Expense On Debt Change Date
Alaunos Therapeutics USD 0 0 Dec/2023
Avita Medical AUD 1.35M 230K Jun/2024
Celltrion KRW 17.04B 1.34B Mar/2025
Dianthus Therapeutics 4.44M 263K Sep/2024
Ionis Pharmaceuticals USD 19M 0 Jun/2025
IQVIA Holdings USD 182M 17M Jun/2025
Moderna USD 1000K 0 Jun/2025
Organon & Co USD 131M 7M Jun/2025
Revvity USD 22.94M 27K Jun/2025
Tectonic Therapeutic USD 17K 5K Jun/2025
Viatris USD 116.6M 1.1M Jun/2025
Xeris Pharmaceuticals USD 7.36M 343K Jun/2025